{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:33:32Z","timestamp":1792226012654,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","award":["H5N1"],"award-info":[{"award-number":["H5N1"]}],"id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009837","name":"Canadian Food Inspection Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2020.01.051","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T08:01:52Z","timestamp":1580457712000},"page":"2387-2395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus"],"prefix":"10.1016","volume":"38","author":[{"given":"Yao","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Landreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuanQun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Brownlie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia van Drunen","family":"Littel-van den Hurk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Gerdts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.051_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.onehlt.2015.03.001","article-title":"One health, multiple challenges: the inter-species transmission of influenza A virus","volume":"1","author":"Short","year":"2015","journal-title":"One Health"},{"issue":"5","key":"10.1016\/j.vaccine.2020.01.051_b0010","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1128\/JVI.79.5.2814-2822.2005","article-title":"Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls","volume":"79","author":"Fouchier","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.01.051_b0015","doi-asserted-by":"crossref","unstructured":"Sato, M., et al. Generation of bat-derived influenza viruses and their reassortants. 2019. 9(1), p. 1158.","DOI":"10.1038\/s41598-018-37830-x"},{"key":"10.1016\/j.vaccine.2020.01.051_b0020","unstructured":"WHO, 2019. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. Available online: https:\/\/www.cdc.gov\/flu\/avianflu\/avian-in-humans.htm#symptoms (accessed on 1 April 2019)."},{"issue":"1","key":"10.1016\/j.vaccine.2020.01.051_b0025","doi-asserted-by":"crossref","first-page":"e14582","DOI":"10.1371\/journal.pone.0014582","article-title":"Highly pathogenic avian influenza (H5N1): pathways of exposure at the animal-human interface, a systematic review","volume":"6","author":"Van Kerkhove","year":"2011","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2020.01.051_b0030","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2020.01.051_b0035","first-page":"6(3)","article-title":"Avian influenza A virus pandemic preparedness and vaccine development","author":"de Vries","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2020.01.051_b0040","unstructured":"WHO, Candidate vaccine viruses and potency testing reagents for influenza A(H5N1). Available online: https:\/\/www.who.int\/influenza\/vaccines\/virus\/candidates_reagents\/a_h5n1\/en\/ (Accessed on 1 April 2019), 2019."},{"issue":"14","key":"10.1016\/j.vaccine.2020.01.051_b0045","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza A\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.01.051_b0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2017.05.010","article-title":"Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets","volume":"508","author":"Sun","year":"2017","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.vaccine.2020.01.051_b0055","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2009.10.019","article-title":"Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1\/2 clinical trial","volume":"28","author":"Keitel","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2020.01.051_b0060","doi-asserted-by":"crossref","first-page":"p. ofz107","DOI":"10.1093\/ofid\/ofz107","article-title":"Safety and immunogenicity of MF59-adjuvanted cell culture-derived A\/H5N1 subunit influenza virus vaccine: dose-finding clinical trials in adults and the elderly","volume":"6","author":"Frey","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2020.01.051_b0065","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.vaccine.2019.02.002","article-title":"Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2020.01.051_b0070","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","article-title":"Safety of AS03-adjuvanted influenza vaccines: a review of the evidence","volume":"37","author":"Cohet","year":"2019","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.01.051_b0075","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: from 1920 to 2015 and beyond","volume":"3","author":"Di Pasquale","year":"2015","journal-title":"Vaccines (Basel)"},{"issue":"24","key":"10.1016\/j.vaccine.2020.01.051_b0080","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.01.051_b0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1189\/jlb.1012497","article-title":"The innate defense regulator peptides IDR-HH2, IDR-1002, and IDR-1018 modulate human neutrophil functions","volume":"94","author":"Niyonsaba","year":"2013","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.01.051_b0090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1021\/bm050790a","article-title":"Synthesis, properties, and biological activity of poly[di(sodium carboxylatoethylphenoxy)phosphazene]","volume":"7","author":"Andrianov","year":"2006","journal-title":"Biomacromolecules"},{"issue":"27","key":"10.1016\/j.vaccine.2020.01.051_b0095","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1016\/j.vaccine.2017.05.029","article-title":"Local innate responses and protective immunity after intradermal immunization with bovine viral diarrhea virus E2 protein formulated with a combination adjuvant in cattle","volume":"35","author":"Sadat","year":"2017","journal-title":"Vaccine"},{"issue":"Pt 5","key":"10.1016\/j.vaccine.2020.01.051_b0100","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1099\/vir.0.062570-0","article-title":"Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity","volume":"95","author":"Garg","year":"2014","journal-title":"J Gen Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2020.01.051_b0105","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.vaccine.2015.01.041","article-title":"The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies","volume":"33","author":"Garg","year":"2015","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2020.01.051_b0110","doi-asserted-by":"crossref","first-page":"7718","DOI":"10.1016\/j.vaccine.2011.07.135","article-title":"Influence of maternal antibodies on active pertussis toxoid immunization of neonatal mice and piglets","volume":"29","author":"Polewicz","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.01.051_b0115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/vaccines2020297","article-title":"Vaccine potentiation by combination adjuvants","volume":"2","author":"Levast","year":"2014","journal-title":"Vaccines (Basel)"},{"issue":"43","key":"10.1016\/j.vaccine.2020.01.051_b0120","doi-asserted-by":"crossref","first-page":"18137","DOI":"10.1073\/pnas.0909696106","article-title":"Glycans on influenza hemagglutinin affect receptor binding and immune response","volume":"106","author":"Wang","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.vaccine.2020.01.051_b0125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4049\/jimmunol.1201060","article-title":"Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity","volume":"190","author":"Hutter","year":"2013","journal-title":"J Immunol"},{"issue":"40","key":"10.1016\/j.vaccine.2020.01.051_b0130","doi-asserted-by":"crossref","first-page":"10112","DOI":"10.1073\/pnas.1810927115","article-title":"Influenza hemagglutinin membrane anchor","volume":"115","author":"Benton","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2020.01.051_b0135","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1038\/nprot.2006.202","article-title":"Using circular dichroism spectra to estimate protein secondary structure","volume":"1","author":"Greenfield","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.vaccine.2020.01.051_b0140","doi-asserted-by":"crossref","unstructured":"Lu Y et al. In vivo characterization of avian influenza A (H5N1) and (H7N9) viruses isolated from canadian travelers. Viruses, 2019. 11(2).","DOI":"10.3390\/v11020193"},{"issue":"2","key":"10.1016\/j.vaccine.2020.01.051_b0145","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4161\/hv.22908","article-title":"Correlates of protection to influenza virus, where do we go from here?","volume":"9","author":"Cox","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2020.01.051_b0150","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1038\/s41467-018-05745-w","article-title":"Nuclear-resident RIG-I senses viral replication inducing antiviral immunity","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"issue":"44","key":"10.1016\/j.vaccine.2020.01.051_b0155","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1016\/j.vaccine.2009.07.107","article-title":"Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A\/Vietnam\/1203\/2004 influenza virus","volume":"27","author":"Biesova","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.01.051_b0160","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1026488408951","article-title":"Insect cells as hosts for the expression of recombinant glycoproteins","volume":"16","author":"Altmann","year":"1999","journal-title":"Glycoconj J"},{"issue":"13\u201314","key":"10.1016\/j.vaccine.2020.01.051_b0165","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0264-410X(00)00395-9","article-title":"Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans","volume":"19","author":"Treanor","year":"2001","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.01.051_b0170","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0042-6822(03)00008-4","article-title":"Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine","volume":"308","author":"Bright","year":"2003","journal-title":"Virology"},{"issue":"18","key":"10.1016\/j.vaccine.2020.01.051_b0175","doi-asserted-by":"crossref","first-page":"9605","DOI":"10.1128\/JVI.78.18.9605-9611.2004","article-title":"Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A\/H3N2 virus hemagglutinin","volume":"78","author":"Abe","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.01.051_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00525","article-title":"Whole-inactivated influenza virus is a potent adjuvant for influenza peptides containing CD8+ T Cell epitopes","volume":"9","author":"Soema","year":"2018","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2020.01.051_b0185","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/infdis\/jiu123","article-title":"A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response","volume":"209","author":"Talaat","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.051_b0190","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-017-0017-5","article-title":"H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines","volume":"2","author":"Wong","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2020.01.051_b0195","doi-asserted-by":"crossref","unstructured":"Sansyzbay, A.R., et al. An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A\/Chicken\/Astana\/6\/05) influenza vaccine is safe and immunogenic in a single dose in humans. Clin Vaccine Immunol 20(8);2013:1314\u20139.","DOI":"10.1128\/CVI.00096-13"},{"issue":"5","key":"10.1016\/j.vaccine.2020.01.051_b0200","doi-asserted-by":"crossref","first-page":"e20052","DOI":"10.1371\/journal.pone.0020052","article-title":"Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines","volume":"6","author":"Lin","year":"2011","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2020.01.051_b0205","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1128\/JCM.02045-09","article-title":"Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling","volume":"48","author":"Jonges","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2020.01.051_b0210","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.2044-8295.1908.tb00176.x","article-title":"The method of \u2018right and wrong cases\u2019(\u2018constant stimuli\u2019) without Gauss's formulae","volume":"2","author":"Spearman","year":"1908","journal-title":"Br J Psychol, 1904\u20131920"},{"issue":"4","key":"10.1016\/j.vaccine.2020.01.051_b0215","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Naunyn-Schmiedebergs Archiv f\u00fcr experimentelle pathologie und pharmakologie"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:31:38Z","timestamp":1778679098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20300773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X20300773"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.051","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}